Autopsy report · NCT06711640

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

“Study withdrawn prior to enrollment due to strategic portfolio decisions following divestiture of the investigational product.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

USWM, LLC (dba US WorldMeds)

Sponsor type

Industry

Conditions

Opioid Withdrawal (Disorder); Opioid Use Disorder

Interventions

LUCEMYRA (lofexidine) tablets

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Group Education & Lifestyle Modification's Impact on Weight Loss & Quality Life of Patients with OA
  “Investigator decision to withdraw study.” (76% match in meaning)
• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
  “Study is withdrawn due to company decision.” (72% match in meaning)
• Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
  “This study was withdrawn for business reasons.” (72% match in meaning)
• A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection
  “Company decision to withdraw before study started” (71% match in meaning)
• EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
  “Study Withdrawn by Sponsor prior to Enrollment.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.